Persistent Atrial Fibrillation Clinical Trial
— AMPER-AFOfficial title:
AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation
A study comparing atrioventricular junction ablation (AVJA) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) with suboptimal heart rate control on optimum medication.
Status | Recruiting |
Enrollment | 480 |
Est. completion date | March 31, 2029 |
Est. primary completion date | December 31, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Treatment with CRT using either a biventricular pacemaker/defibrillator or conduction system pacemaker (>6 months) - Diagnosis of AF and classified as: permanent AF or recurrent persistent AF, requiring emergency visits and/or hospitalizations (at least one in recent year) - Optimized HF medical treatment and rate control medication - BiVP% + ventricular premature complex (VPC%) <99% and >85% during the minimum period of 1 month while already on optimum medical therapy (applicable only for patients with permanent AF) - Age >18 and <85 years - Signed informed consent Exclusion Criteria: - myocardial infarction (MI) or coronary artery bypass graft (CABG) <3 months - Technical failure of the CRT system - Intentional preference for spontaneous AV conduction - Expected survival <1 year - Other significant comorbidities and/or conditions that interfere with the proper conduction of the trial - Dementia as assessed by mini-mental test (<23 points) |
Country | Name | City | State |
---|---|---|---|
Czechia | St. Anne's University Hospital Brno | Brno | South Moravian Region |
Czechia | University Hospital Brno | Brno | South Moravian Region |
Czechia | Hospital Ceské Budejovice | Ceské Budejovice | South Bohemian Region |
Czechia | Regional Hospital Liberec | Liberec | Liberec Region |
Czechia | University Hospital Olomouc | Olomouc | Olomouc Region |
Czechia | University Hospital Ostrava | Ostrava | Moravian-Silesian Region |
Czechia | Institute of Clinical and Experimental Medicine | Prague | |
Czechia | Military University Hospital Prague | Prague | |
Czechia | Hospital Podlesí, Inc. | Trinec | Moravian-Silesian Region |
Lead Sponsor | Collaborator |
---|---|
University Hospital Ostrava |
Czechia,
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Bohm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferovic P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021 Mar;23(3):352-380. doi: 10.1002/ejhf.2115. Epub 2021 Mar 3. — View Citation
Dong K, Shen WK, Powell BD, Dong YX, Rea RF, Friedman PA, Hodge DO, Wiste HJ, Webster T, Hayes DL, Cha YM. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm. 2010 Sep;7(9):1240-5. doi: 10.1016/j.hrthm.2010.02.011. Epub 2010 Feb 13. — View Citation
Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol. 2012 Feb 21;59(8):719-26. doi: 10.1016/j.jacc.2011.10.891. — View Citation
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. No abstract available. Erratum In: Eur Heart J. 2022 May 1;43(17):1651. — View Citation
Huber A, Oldridge N, Hofer S. International SF-36 reference values in patients with ischemic heart disease. Qual Life Res. 2016 Nov;25(11):2787-2798. doi: 10.1007/s11136-016-1316-4. Epub 2016 Jun 18. — View Citation
Hussain A, Misra A, Bozkurt B. Endpoints in Heart Failure Drug Development. Card Fail Rev. 2022 Jan 18;8:e01. doi: 10.15420/cfr.2021.13. eCollection 2022 Jan. — View Citation
Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009 Jan 27;53(4):355-60. doi: 10.1016/j.jacc.2008.09.043. — View Citation
Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006 Mar 21;113(11):1424-33. doi: 10.1161/CIRCULATIONAHA.105.584102. Epub 2006 Mar 13. — View Citation
Ousdigian KT, Borek PP, Koehler JL, Heywood JT, Ziegler PD, Wilkoff BL. The epidemic of inadequate biventricular pacing in patients with persistent or permanent atrial fibrillation and its association with mortality. Circ Arrhythm Electrophysiol. 2014 Jun;7(3):370-6. doi: 10.1161/CIRCEP.113.001212. Epub 2014 May 17. — View Citation
Packer M. Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective. Circulation. 2016 Nov 22;134(21):1664-1678. doi: 10.1161/CIRCULATIONAHA.116.023538. — View Citation
Waranugraha Y, Rizal A, Setiawan D, Aziz IJ. The Benefit of Atrioventricular Junction Ablation for Permanent Atrial Fibrillation and Heart Failure Patients Receiving Cardiac Resynchronization Therapy: An Updated Systematic Review and Meta-analysis. Indian Pacing Electrophysiol J. 2021 Mar-Apr;21(2):101-111. doi: 10.1016/j.ipej.2020.12.005. Epub 2021 Feb 4. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Heart failure (HF) events | The number of HF events will be observed. | 3 years | |
Primary | 36-Item Quality of Life (QoL) | QoL will be assessed using the 36-Item Quality of Life Questionnaire. QoL will be evaluated at 12, 24 and 36 months as a sum of points that are assigned to individual outcome measures, specifically to their change compared to the baseline.
To score the SF-36, scales are standardized to obtain a score ranging from 0 to 100. Higher scores indicate better health status, and a mean score of 50 has been articulated as a normative value for all scales. |
3 years | |
Primary | Minnesota Living with Heart Failure Questionnaire (MLHFQ) | MLHFQ values will be recorded and evaluated at 12, 24 and 36 months. The questionnaire is comprised of 21 questions around several physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. The patient marks a 0 (zero) to 5 (five) scale to indicate the extent to which each itemized adversity of heart failure has prevented the patient from living as they wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses. | 3 years | |
Primary | Dose of loop diuretics | Change in the dose of loop diuretics will be observed and recorded. This parameter will be evaluated at 12, 24 and 36 months as an increase or decrease of the dose compared to the baseline. | 3 years | |
Primary | NYHA classification | Changes in the New York Heart Association classification (NYHA) will be observed. The NYHA classification values will be evaluated at 12, 24 and 36 months. The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity; the limitations/symptoms are in regards to normal breathing and varying degrees in shortness of breath and or angina pain. | 3 years | |
Secondary | All-cause death | Patient deaths from all causes will be observed, recorded and analysed. | 3 years | |
Secondary | Death from cardiovascular diseases (CV death) | Incidents of CV death will be observed, recorded and analysed. | 3 years | |
Secondary | Combined heart failure (HF) death and HF hospitalization | Incidents of combined heart failure (HF) death and HF hospitalization will be observed, recorded and analysed. | 3 years | |
Secondary | Time-averaged proportional change in NT-pro-Brain Natriuretic Peptide (NT-pro-BNP) | The time-averaged proportional change in NT-pro-BNP will be observed, recorded and analysed. | 3 years | |
Secondary | Days in the hospital because of heart failure (HF) | The number of days in the hospital because of heart failure (HF) will be recorded. | 3 years | |
Secondary | Time-averaged change in the NYHA class | The time-averaged change in the NYHA class will be observed, recorded and analysed. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT03650556 -
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
|
N/A | |
Recruiting |
NCT04085731 -
Driver-guided Ablation of Persistent Atrial Fibrillatiom
|
||
Withdrawn |
NCT02344394 -
Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation
|
N/A | |
Terminated |
NCT01683045 -
Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats
|
N/A | |
Completed |
NCT01694563 -
ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT03643224 -
DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
|
N/A | |
Withdrawn |
NCT05093868 -
Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)
|
N/A | |
Completed |
NCT05152966 -
Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
|
N/A | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Active, not recruiting |
NCT06124690 -
Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas
|
N/A | |
Not yet recruiting |
NCT05454111 -
CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation
|
N/A | |
Completed |
NCT06260670 -
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT05077670 -
Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
|
||
Withdrawn |
NCT03835338 -
WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm
|
N/A | |
Completed |
NCT02275104 -
Multimodal Image Processing Software to Guide Cardiac Ablation Therapy
|
N/A | |
Not yet recruiting |
NCT05565183 -
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
|
N/A | |
Completed |
NCT02274857 -
Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
|
N/A |